Introduction: Adenosquamous carcinoma of the pancreas is a rare variant of exocrine pancreatic tumor. This type of tumor is extremely rare as only few similar cases have been described in the literature.
Introduction
Pancreatic cancer is the 6th leading cause of death in Europe, while the incidence rate approaches the mortality rate [1] . Adenosquamous carcinoma is a rare entity of pancreatic cancer. Institutional reviews of autopsy and surgical specimens suggest an incidence of approximately 4% of all pancreatic neoplasms. It has been variously referred to as adenoacanthoma, mixed squamous and adenocarcinoma, and mucoepidermoid carcinoma. Only a few cases, 150 approximately, have been reported in the accessible literature, until 2008 [2] . Largest series published are from Rahemtullah et al and Kardon et al, with 14 and 25 cases respectively [3, 4] .
Case presentation
A 72-years-old Caucasian Greek male patient presented with epigastric pain of low intensity, jaundice and loss of appetite for the past 30 days. The patient was a heavy smoker (50 cig/day) and consumed alcohol (wine) occasionally, in small quantities. Physical examination revealed a distressed male patient with a body temperature of 37°C, blood pressure of 130/85 mmHg and pulse rate about 85/min. Painless jaundice was the presenting symptom and Courvoisier sign was present. The patient had no sings of ascites, or gastrointestinal obstruction. Hematocrit was 31%, white blood cells 10630/μL with neutrophil prevalence 77% and platelets 341.000/μL. Biochemical profile showed Tbil: 7.50 mg/dl, Dbil: 5.50 mg/ dl, SGOT: 109 U/L, SGPT: 145 U/L, γGT: 517 U/L, ALP: 467 U/L, LDH: 503 U/L, CA125: 244, 50 U/L, CA19.9: 51.30 U/L. The patient was receiving digoxin and warfarin for chronic atrial fibrillation. Thin section computer tomography showed dilatation of the gallbladder and intra/ extrahepatic biliary tree, while a 5 cm mass of the uncinate process of the pancreas was identified to invade the intrapancreatic portion of the bile duct, as well as the 2 nd and 3 rd portion of the duodenum (Figure 1 ). There was no extrapancreatic disease, no extension to the superior mesenteric artery and celiac axis. The superior mesentericportal confluence was patent. The decision for surgical intervention was taken, and a pylorus preserving pancreaticoduodenectomy was performed after exploratory laparoscopy. The patient had an uneventful postoperative course and discharged on the 11 th day.
Histological evaluation of the pancreatic tumor showed an adenosquamous carcinoma which was extensively infiltrative with perineural invasion, involvement of peripancreatic lymph nodes and all the thickness of the duodenum wall. The tumor elicited an intense desmoplastic stromal reaction and areas of necrosis ( Figure 2 ). Focal areas of high grade pancreatic intraepithelial neoplasia were seen. The tumor exhibited a biphasic malignant growth identified as, well to moderate differentiated adenocarcinoma and well to poorly differentiated squamous cell carcinoma ( Figure 3 ). The adenocarcinoma component contained ductal or glandular structures with focal intracellular or extracellular mucin ( Figure 4 ). Squamous differentiation was characterized by irregular and infiltrative nests or sheets of polygonal cells with distinct cellular borders, intercellular bridges, eosiniphilic cytoplasm and varying degrees of keratinization ( Figure 5 ). These two different patterns could be seen separated topographically within the substance of the tumor or intimately admixed. Six of the 15 resected lymph nodes were positive for metastatic tumor which was composed of squamous carcinoma only ( Figure 6 ). 
Discussion
The incidence of adenosquamous carcinoma of the pancreas ranges among studies from 3% [5] to 11.1% [6] , however the true incidence is not known since this is an aggressive tumor and most patients have not undergone surgery or autopsy. A few theories have been reported concerning the formation of adenosquamous carcinoma in an organ, where almost exclusively adenocarcinoma is the predominant cancer involved. One such theory postulates that a metaplastic squamous epithelium undergoes malignant transformation. Additionally, a preexisting adenocarcinoma could undergo malignant change and finally, a primitive cell may be capable of differentiating to either squamous or adeno component [6] .
Preoperative diagnosis is often difficult, as there are no specific characteristics that can identify the squamous component in the lesion. However, Ga-67 citrate scintig-(H&E ×100) Adenocarcinoma similar to ductal carcinoma (H&E ×100) Lymph node metastasis only from the squamous element Figure 6 (H&E ×100) Lymph node metastasis only from the squamous element.
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raphy may be useful in detecting adenosquamous carcinoma of the pancreas [7] . On CT imaging, features suggestive of adenosquamous carcinomas of the pancreas include large infiltrative lesions and the presence of central necrosis [8] . Nabae et al. concluded that the presence of central necrosis in an infiltrative huge pancreatic tumor seems to be suggestive of the diagnosis of adenosquamous carcinoma of the pancreas [9] . The role of endoscopic US-guided FNA biopsy remains controversial.
Once the diagnosis is established either preoperative or postoperative, the question that rises refers to the best treatment modality for this aggressive tumor of the pancreas. From the literature reviewed, there is no study with significant statistical power to address that question. Smoot et al. demonstrated a longer survival for patients that can undergo an R0 resection. For R0 resection median survival was 14.4 months compared to 8 months for R1 and 4.8 months for patients undergoing palliative therapies [10] . Hsu JT et al. showed that the cumulative survival rates of 12 patients with pancreatic adenosquamous carcinomas, ranged from 1.12 to 22.42 months, with a median of 4.41 months. Additionally, patients with pancreatic adenosquamous carcinomas had shorter median survival compared to those with adenocarcinoma 6.51 months vs. 9.76 months [11] . Multidisciplinary treatments including aggressive surgery, intraoperative radiation therapy, and locoregional chemotherapy have also been reported to improve the survival of patients with adenosquamous carcinoma of the pancreas and to inhibit liver metastasis and local recurrence [12] . Shibagaki K et al. presented a case of successful use of chemoradiotherapy with low-dose cispastin and additional combined chemotherapy with S-1 and cisplatin for unresectable pancreatic adenosquamous carcinoma [13] . Tanaka N et al. suggested that combined chemotherapy with cytokines (IFN-a plus TNF-a) and 5-FU may be a therapeutic modality for advanced pancreatic cancer [14] . Wilkowski R, et al. concluded that gemcitabine and cisplatin can safely be combined with external beam radiation. This preoperative treatment approach is highly effective and appears to improve survival in patients whose tumors are rendered completely resectable [15] . However, there have been no sufficient studies that could propose a treatment modality for this rare tumor.
Conclusion
It has become clear that this type of cancer has a dismissal prognosis. Even with aggressive therapies median survival is poor. More studies are needed to address the role of surgery and the use of adjuvant therapy, however this is quite difficult as this tumor entity is extremely rare. Since squamous cell carcinomas seem to respond satisfactory to chemoradiotherapy regimens based on 5-FU, this combination could be potentially used as adjuvant therapy in patients with resectable squamous cell pancreatic cancer, or as palliative therapy for unresectable tumors. R0 resection remains the gold standard for those individuals who are fit enough to undergo such a major operation.
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